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ABSTRACT:
In human cells TORC1 mTOR (target of rapamycin) protein kinase complex 
renders heat shock transcription factor 1 (Hsf1) competent for stress activation. In 
such cells, as well as in yeast, the selective TORC1 inhibitor rapamycin blocks this 
activation in contrast to Hsp90 inhibitors which potently activate Hsf1. Potentially 
therefore rapamycin could prevent the Hsf1 activation that frequently compromises 
the efficiency of Hsp90 inhibitor cancer drugs. Little synergy was found between the 
effects of rapamycin and the Hsp90 inhibitor radicicol on yeast growth. However 
certain rapamycin resistance mutations sensitised yeast to Hsp90 inhibitor treatment 
and an Hsp90 mutation that overactivates Hsf1 sensitised cells to rapamycin. 
Rapamycin inhibition of the yeast Hsf1 was abolished by this Hsp90 mutation, as 
well as with the loss of Ppt1, the Hsp90-interacting protein phosphatase that is 
the ortholog of mammalian PP5. Unexpectedly Hsf1 activation was found to have a 
requirement for the rapamycin binding immunophilin FKBP12 even in the absence of 
rapamycin, while TORC1 “bypass” strains revealed that the rapamycin inhibition of 
yeast Hsf1 is not exerted through two of the major downstream targets of TORC1, 
the protein phosphatase regulator Tap42 and the protein kinase Sch9 – the latter the 
ortholog of human S6 protein kinase 1.
 Significance: A problem with most of the Hsp90 inhibitor drugs now in cancer 
clinic trials is that they potently activate Hsf1. This leads to an induction of heat shock 
proteins, many of which have a “pro-survival” role in that they help protect cells from 
apopotosis.  As the activation of Hsf1 requires TORC1, inhibitors of mTOR kinase could 
potentially block this activation of Hsf1 and be of value when used in combination 
drug therapies with Hsp90 inhibitors. However many of the mechanistic details of 
the TORC1 regulation of Hsf1, as well as the interplay between cellular resistances 
to rapamycin and to Hsp90 inhibitors, still remain to be resolved.
INTRODUCTION
Hsp90, heat shock transcription factor 1 
and mTOR kinase – a triage driving cancer 
progression. 
Heat shock protein 90 (Hsp90) provides a molecular 
chaperone function essential for the conformational 
maturation, activation and maintenance of proteins 
essential for sustaining all of the hallmarks of cancer. As 
such it is now a prime target for drug development, with 
several Hsp90 inhibitors currently in cancer clinic trials 
[1, 2]. Inhibitors of Hsp90 may prove to be most useful 
for treating those malignancies where the oncogene driver 
(e.g. HER2, ALK) has a high dependency on Hsp90 or, in 
situations such as multiple myeloma, where the buffering 
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of proteotoxic stress is critical for survival [2]. One factor 
that often compromises the efficiency of these drugs is 
their tendency to activate heat shock transcription factor 1 
(Hsf1). This leads to the induction of heat shock proteins, 
many of which have a “pro-survival” role in that they help 
to protect cancer cells from apopotosis [2, 3]. Attention is 
therefore being directed to developing combination drug 
therapies that will enable a dual targetting of both Hsf1 
and Hsp90 [4]. Like Hsp90, Hsf1 is itself a key permissive 
factor in cancer progression [5] and overexpressed in 
certain aggressive cancers (e.g. hepatocellular carcinoma 
[4]). Furthermore Hsf1 inhibition may not be toxic to 
normal tissues since Hsf1 knockout mice are viable [5].
A number of small molecule inhibitors of Hsf1 
have been identified [6-10]. However the recent discovery 
that the activation of Hsf1 requires mTOR (target of 
rapamycin) protein kinase [11] indicates the possibility 
that TOR kinase inhibitors might be as effective as these 
inhibitors which act directly on Hsf1 in blocking the Hsf1 
activation with by Hsp90 inhibitor drug treatment. Until 
now, studies that have investigated the combinatorial 
use of the selective TORC1 inhibitor rapamycin with an 
Hsp90 inhibitor have not addressed whether the observed 
effects might be partly due to the rapamycin abrogating 
the induction of Hsf1 [12-14]. However while this paper 
was under review, an unbiased drug screen was reported 
for compounds that could block the Hsf1-directed 
increases in Hsp70 with  Hsp90 inhibition. It revealed that 
phosphoinositide 3-kinase (PI3K) and mTOR inhibitors 
could effectively inhibit this increase and potentiate the 
antitumour efficacy of an Hsp90 inhibitor in many in vivo 
models [15].
As with both Hsp90 and Hsf1, mTOR is often 
overactivated in cancer; certain gain of function mutations 
in the mTOR kinase domain being tumorigenic in 
animal models [16, 17]. This protein kinase forms the 
catalytic subunit of two distinct multiprotein complexes 
(TORC1/2), complexes which are central to many of the 
pathways regulating cell growth and proliferation since 
they act as the integration “hubs” for diverse signalling 
inputs [16]. Studies of rapamycin, the natural antibiotic 
identified as the first highly selective inhibitor of TORC1 
(see below), either for treating cancer or to promote a 
healthier, longer life have been well publicized (especially 
since this agent has been shown to extend lifespan in 
flies and mice [18, 19]). Unfortunately the results of the 
cancer trials of rapamycin and its analogues (rapalogues) 
have mostly been undistinguished, despite isolated 
successes. In some cancer cells rapamycin actually 
promotes oncogenic activity [13], due to an activation of 
AKT and other signalling molecules of the IGF-1R/IRS-
1 signalling system which reflects the loss of a negative 
feedback regulation on IRS-1 and TORC2 [20, 21]. In 
addition it can increase NFκB activity and upregulate the 
expression of IGF-1R and HER2 [22]. Rapamycin also 
has some undesirable side effects, with low dose, long 
term treatment inducing insulin resistance [23]. Attention 
is therefore now being directed to the development of 
inhibitors that will selectively target the catalytic site of 
mTOR, drugs that will inhibit both TORC1 and TORC2 
[24, 25] (identifier: www.clinicaltrials.gov). There are 
indications that such drugs might be highly effective 
when used in combination with Hsp90 inhibitors. Thus 
both mTOR inhibitors [13] and Hsp90 inhibitors [1, 2] 
exert potent antiangiogenic activity, with the expectation 
that improved antiangiogenic therapies may result from 
a combined use of these agents. The antiangiogenic 
properties of the TORC1 inhibitor rapamycin are partly 
attributable to an inhibition of PI3/AKT signalling in 
endothelial cells, a process strongly activated by vascular 
endothelial growth factor (VEGF) [26]. The synergism 
between rapamycin and Hsp90 inhibitors in cultured 
breast cancer and multiple myeloma has generally been 
attributed to key downstream targets of IRS-1 and TORC2 
signalling being “clients” of Hsp90 [12, 13]. Indeed the 
rapamycin-promoted oncogenic activity observed in 
certain tumors employs a number of signaling components 
highly dependent on Hsp90 (e.g. IGF-1R, IRS-1, HER2, 
Erk). It should therefore be abrogated by Hsp90 inhibition. 
However the discovery that the activation of Hsf1 in 
human cells requires TORC1 [11], opens the possibility 
that the results of combinatorial usage of rapamycin with 
an Hsp90 inhibitor may be partly caused by the rapamycin 
inhibition of TORC1 abolishing the Hsf1 activation with 
inhibition of Hsp90. 
In this study we have employed well-characterised 
mutant strains of yeast to unravel specific details of the 
interplay between cellular resistances to rapamycin and 
an Hsp90 inhibitor; of the TORC1 regulation of Hsf1; 
of whether the rapamycin inhibition of Hsf1 might be 
overridden by Hsp90 inhibitor treatment; and of how 
Hsp90 chaperone system defects might impact on the 
rapamycin inhibition of Hsf1 activity.
RESULTS
Hsp90 inhibitor treatment does not sensitise yeast 
cells to rapamycin.
On the basis of current evidence cellular resistances 
to rapamycin and to Hsp90 inhibitors might be expected 
to be, at least to a degree, interdependent. Firstly, both 
in mammalian systems (see Introduction) and in yeast 
[27] Hsp90 inhibitors activate Hsf1, whereas rapamycin 
inhibits the activation of Hsf1 [11](see below). Secondly, 
the activation of Hsf1 downregulates TORC1 activity 
and sensitises yeast to rapamycin [28]. Initially therefore 
we investigated whether there are any synergistic effects 
between the inhibitory effects of rapamycin and an Hsp90 
inhibitor on yeast growth and whether these might be 
Oncotarget5056www.impactjournals.com/oncotarget
influenced by the loss of the inducible heat shock response.
For this analysis we used two yeast strains (NSY-A, 
NSY-B; Table 1) which differ in whether they express 
either a full length or a truncated (residue 1-583) forms 
of Hsf1. The latter, a form of this transcription factor 
that lacks the C-terminal activatory domain, provides the 
Hsf1 function needed for growth to 37°C yet lacks much 
of the inducible heat shock response [29, 30]. The cells 
expressing this truncated (1-583) Hsf1 were appreciably 
more sensitive to the Hsp90 inhibitor radicicol, consistent 
with their lower levels of Hsp90 [31]. However they were 
not sensitised to either rapamycin or caffeine (Fig. 1)(the 
actions of caffeine in yeast having been largely attributed 
to its inhibition of TORC1 [32]). Importantly, there was 
very little synergy between the growth inhibitory effects 
of the Hsp90 inhibitor radicicol and either rapamycin or 
caffeine, irrespective of whether the cells were expressing 
the normal full length Hsf1 or the truncated (1-583) Hsf1 
(Fig. 1). Therefore, though Hsp90 inhibition normally 
leads to an activation of Hsf1 and the activation of Hsf1 
in the absence of stress has the potential sensitise cells 
to rapamycin [28], neither the presence nor absence 
of a stress-activatable Hsf1 appeared to be causing any 
appreciable synergy between the inhibitory effects of these 
two drugs, at least in this model system.
Mutations that confer rapamycin resistance in 
yeast impact on Hsp90 inhibitor sensitivity.
The original genetic identification of TOR kinase 
as the target of rapamycin came through the analysis of 
mutations causing rapamycin resistance in yeast [33]. 
Resistance was generated either through the loss of the 
immunophilin that binds rapamycin (FKBP12) or with 
alterations to a conserved serine residue within the 
FKBP12-rapamycin complex binding (FRB) domain of 
either of the two distinct TOR proteins in yeast (S1972R in 
Tor1 (the TOR1-1 allele); S1975I in Tor2 (TOR2-1)). Later 
rapamycin resistance was demonstrated in mammalian 
cells with the mutation of this conserved serine (S2035) 
in the single mammalian TOR kinase, mTOR [34, 35]. 
Not only does the TOR1.1 mutation generate rapamycin 
resistance, but it also diminishes Tor kinase activity [36]. 
Extending these studies in yeast we found that both TOR1-
1 and TOR2-1 generated a partial sensitivity to radicicol 
(Fig. 2a), the most potent natural inhibitor of Hsp90 [37]. 
Whilst assembly of the TORC1/2 complexes 
needs the Hsp90 chaperone system [38] no evidence has 
emerged to date to indicate that the enzymatic activities 
of these complexes are Hsp90-dependent. Of TORC1/2 
subunits, only Raptor (Kog1 in yeast) has been shown to 
interact with Hsp90 [39, 40]. Therefore we investigated 
whether this effect of TOR1-1 and TOR2-1 sensitising 
cells to Hsp90 inhibitors (Fig. 2a) might be correlated with 
an altered regulation of Hsf1. Consistent with this, it was 
found that these mutations reduced the cellular capacity 
for induction of a heat shock element (HSE) driven 
β-galactosidase gene reporter of Hsf1 activity (HSE-lacZ; 
Fig. 2b). An increased sensitivity to Hsp90 inhibition 
and dramatically lowered HSE-lacZ induction were also 
found in the tor1Δ mutant (Figs. 2a, 3a,c), a strain which 
has lowered TORC1 kinase activity due to its lack of the 
Fig 1: TreeView representation of the growth (46h 28°C) of strains NSY-A (HSF) and NSY-B (hsf1-583) in the presence 
of various combinations of radicicol and rapamycin (left) or radicicol and caffeine (right); the data being represented 
as a percentage of the growth in the absence of drug. 
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nonessential Tor1 protein (of the two Tor kinase proteins 
in Saccharomyces cerevisiae yeast, Tor1 is nonessential 
and Tor2 essential, both Tor1 and Tor2 being capable of 
forming the catalytic subunit of TORC1 whereas TORC2 
contains only Tor2).
Hsf1 activation is lost in yeast, not just with the 
rapamycin inhibition of TORC1, but also with 
loss of the rapamycin binding immunophilin 
FKBP12.
The requirement for TORC1 to render Hsf1 
competent for stress activation is clearly apparent from the 
effects of the selective TORC1 inhibitor rapamycin. We 
found that in yeast, as in human cells [11], administration 
of this antibiotic rapidly abolished Hsf1 induction (Figs. 
2b; 3a,c). Rapamycin must be exerting this effect through 
its inhibition of TORC1, since it did not inhibit the stress 
induction of Hsf1 in TOR1-1 and TOR2-1 strains, where 
the above mutations are causing a genetically dominant 
loss of the rapamycin inhibition of TORC1 (Fig. 2b). 
As described above, rapamycin resistance also arises 
with the loss of FKBP12, the immunophilin that binds 
rapamycin. When we investigated HSE-lacZ expression 
in a strain that lacks this FKBP12 (the fpr1Δ mutant; 
Fig 2 a: Serial dilutions of wild type, tor1Δ, TOR1-1, 
TOR2-1 single mutant and tor1Δ TOR2-1 double mutant 
cells of the BY4741 genetic background, pinned onto rich 
(YPD) medium containing the indicated inhibitor and 
photographed after 2d growth at 28°C.
b. Measurements of HSE-lacZ reporter gene induction in the 
wild type, TOR1-1 and TOR2-1 strains in (a). Cells were treated 
with or without 100nM rapamycin for 30min at 25°C, HSE-
lacZ expression being measured after a further 1h at 25°C or 
following a 25-39°C 1h heat shock (mean and SD of 8 assays on 
each culture; two-tailed t-test; *=p<0.05; **=p<0.01).
Fig 3 a: Measurements of HSE-lacZ induction in wild 
type, tor1Δ and FKBP12-deficient (fpr1Δ) cells of the 
BY4741 genetic background. Cells were treated with or 
without 100nM rapamycin for 30min at 25°C prior to HSE-lacZ 
induction, either by heat shock (25-39°C for 1h) or the addition 
of 100µM radicicol (1h 25°C). b. The same strains pinned onto 
rich (YPD) medium with or without radicicol and photographed 
after 2d growth at either 28°C or 37°C. c. HSE-lacZ induction 
in BY4741fpr1Δ mutant cells containing a LEU2 plasmid borne 
gene for either the wild type (FPR1) or the F43Y mutant (fpr1-
F43Y) FKBP12.  
Fig 4: The rapamycin inhibition of HSE-lacZ induction 
is still apparent in tip41Δ and Sch92D3E single mutant, 
also a tip41Δ, Sch92D3E double mutant, TORC1 “bypass” 
strains (cells of the TB50a genetic background; Table 1). 
The conditions of heat shock and rapamycin treatment were as 
in Figs. 2,3. 
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Fig. 3a) we unexpectedly found an almost total absence 
of stress activation even in the absence of rapamycin. An 
FPR1 gene-bearing plasmid was able to restore HSE-lacZ 
activation in this strain (Fig. 3b). Therefore the stress 
activation of Hsf1 in yeast has a hitherto undiscovered 
requirement for FKBP12. 
Binding of the inhibitory FKBP12/rapamycin 
complex to TORC1 is known not to require the peptidyl 
prolyl isomerise activity of the immunophilin FKBP12 
[34]. To analyse whether the activation of Hsf1 has a 
requirement for this peptidyl prolyl isomerase activity 
we expressed both wild type and F43Y mutant forms of 
FKBP12 in fpr1Δ cells. F43Y corresponds to a mutation 
which, in the human FKBP12, lowers the peptidyl prolyl 
isomerise activity 1000-fold [34]. This F43Y mutation did 
not abolish the capacity of an introduced FPR1 gene to 
rescue stress activation of Hsf1 in fpr1Δ cells (Fig. 3b), 
revealing that FKBP12 does not require its peptidyl prolyl 
isomerase activity in order to facilitate the activation of 
Hsf1. 
The Hsf1 activation defects of tor1Δ and fpr1Δ 
mutant cells (Fig. 3a) are one probable reason why both of 
Fig 5: a FPR1+ and fpr1Δ cells of the PP30 genetic background expressing either the wild type or the E381K mutant Hsp82 
as their sole Hsp90, pinned onto rich (YPD) medium containing the indicated level of rapamycin and photographed after 
2d growth at 28°C. b-d Measurements of HSE-lacZ reporter gene expression in: (b) wild type, hsp82-E381K and  hsp82-E381K fpr1Δ 
strains of the PP30 genetic background; (c) wild type and ppt1Δ strains of the BY4741 genetic background; and (d) strains of PP30 genetic 
background expressing Hsp82 the wild type or the –EEVD mutant Hsp82 as their sole Hsp90. The conditions of heat shock and rapamycin 
treatment were as in Figs. 2,3.  
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these mutants are slightly temperature sensitive (identifier: 
www.yeastgenome.org/)(Fig. 3c). Only at higher 
temperatures did the loss of FKBP12 cause an increased 
cellular sensitivity to the Hsp90 inhibitor radicicol (the 
fpr1Δ mutant, Fig. 3c).
Rapamycin inhibition of Hsf1 is not exerted 
through the TORC1 regulation of Tap42 or Sch9, 
the latter the ortholog of mammalian S6 protein 
kinase 1.
In yeast one can address the issue of whether the 
TORC1 activation of Hsf1 is direct, or operates through 
the known signalling events downstream of TORC1. 
This model organism can be engineered so that each 
downstream target phosphorylated by TORC1 is rendered 
independent of TORC1 activity [41]. Yeast TORC1 is 
known to directly phosphorylate Tap42 (a regulator of 
PP2A and PP2A-like protein phosphatases [42]), Sch9 
(the budding yeast ortholog of the mammalian S6 protein 
kinase 1 (S6K1) [41]) and Atg13, a subunit of the Atg1 
kinase complex. All three targets are also regulated 
by other protein kinases (Sch9 by Pkh1/2, functional 
orthologs of mammalian phosphoinositide-dependent 
protein kinase 1; Atg13 by protein kinase A [43]). Tap42 is 
rendered constitutively active and independent of upstream 
signals from TORC1 with the loss of its negative regulator, 
Tip41 [44]. Sch9, the protein kinase whose inactivation 
causes most of the rapamycin-induced changes to the yeast 
phosphoproteome [45], is rendered constitutively active 
and independent of upstream signals from TORC1 when 
the amino acids normally phosphorylated by TORC1 at its 
C-terminus are replaced by acidic residues (the Sch92D3E 
allele [41]).
To determine whether the TORC1 regulation of 
Hsf1 in yeast (Fig. 2b,c) acts through either Tap42 or 
Sch9 we investigated how rapamycin affects the stress 
induction of Hsf1 in TORC1 bypass (tip41Δ, Sch92D3E 
single mutant and tip41Δ, Sch92D3E double mutant) strains 
(Table 1). We were unable to detect any altered sensitivity 
to Hsp90 inhibitors in such strains (not shown). Hsf1 
induction was still inhibited by rapamycin in tip41Δ 
cells, lacking the TORC1 regulation of Tap42; Sch92D3E 
cells lacking the TORC1 regulation of Sch9; as well as 
in the tip41Δ, Sch92D3E double mutant (Fig. 4). Therefore 
Table 1: Strains used in this study
Strain Genotype Source
W303-1a MATα; ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 Euroscarf
NSY-A W303-1a hsf1::LEU2 (pRS314-HSF) [54]
NSY-B W303-1a hsf1::LEU2 (pRS314-HSF(1-583)) [54]
BY4741 MATa  his3-∆1 leu2-∆0 met15-∆ ura3-∆0 Euroscarf
BY4741 fpr1∆ BY4741 fpr1∆kanMX4 Research Genetics
BY4741 tor1∆ BY4741 tor1∆kanMX4 Research Genetics
BY4741 TOR1.1 BY4741 TOR1.1 This study
BY4741 TOR2.1 BY4741 TOR2.1 This study
BY4741 tor1∆ TOR2.1 BY4741 tor1∆kanMX4 TOR2.1 This study
BY4741 ppt1∆ BY4741 ppt1∆kanMX4 Research Genetics
TB50a MATa; ura3-52, trp1, leu2, his3, rme1 Robert Loewith
AH308 TB50a SCH9::pRS304 Alexandre Huber
AH333 TB50a sch92D3E::pRS304 Alexandre Huber
AH386 TB50a tip41::hphMX4 SCH9::pRS304 Alexandre Huber
AH387 TB50a tip41::hphMX4 sch92D3E::pRS304 Alexandre Huber
PP30-HSP82
MATa trp1-289, leu2-3,112, his3-200, ura3-52, ade2-
101oc, lys2-801am, hsc82::kanMX4, hsp82::kanMX4 
[pHSCprom-HSP82 a (LEU2)]
[27]
PP30-hsp82(E381K) PP30 [pHSCprom-hsp82(E381K) a (LEU2)] This study
PP30-HSP82 fpr1∆ PP30 fpr1∆hphMX4 [pHSCprom-HSP82 a (LEU2)] This study
PP30-hsp82(E381K) 
fpr1∆ 
PP30 fpr1∆hphMX4 [pHSCprom-hsp82(E381K)a 
(LEU2)] This study
PP30-hsp82(-EEVD) PP30 [pHSCprom-hsp82(-EEVD) a (LEU2)] This study
a The sole Hsp90 gene in this strain, expressed under HSC82 promoter control and borne on a LEU2 plasmid. 
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the Hsf1 inactivation upon rapamycin inhibition of 
TORC1 (Fig. 2b) does not involve the downregulation of 
TORC1 signalling through either Tap42 or Sch9. Instead 
it is possible that TORC1 acts more directly upon Hsf1 in 
order to render the latter competent for stress activation. It 
should be noted that a number of the strains studied here 
(e.g. TOR1-1 and TOR2-1 (Fig. 2b); Sch92D3E (Fig. 4)) are 
also defective in the rapamycin-mediated phosphorylation 
of eIF2α, leading to downregulation of protein synthesis 
[41]. The rapid rapamycin inhibitions of HSE-lacZ 
expression, measured as loss of β-galactosidase induction 
in these experiments (Figs. 2b, 3a,c), are primarily not 
therefore a reflection of the general downregulation of 
protein synthesis which normally accompanies the loss of 
Sch9 activity.
Rapamycin inhibition of Hsf1 can be lost with 
mutation of the Hsp90 chaperone system.
Hsp90 inhibitors potently activate Hsf1, due to the 
inverse correlation between the activity of Hsf1 and the 
activity of the Hsp90 chaperone. The resultant induction 
of antiapoptotic heat shock proteins is one of the main 
drawbacks to the use of these drugs in cancer therapy (see 
Introduction). In yeast, los of this Hsp90 suppression of 
Hsf1 can occur not just through Hsp90 inhibitor treatment 
[27], but also with mutation to Hsp90 itself (e.g. the 
hsp82-E381K mutant [27, 46]) and with defects in certain 
nonessential cochaperones of the Hsp90 chaperone 
system [47]. Strain PP30-hsp82(E381K)(Table 1) possess 
a point mutation in its Hsp90 that causes its Hsf1 to be 
constitutively hyperactive even in the absence of stress 
[46] (this Hsf1 activation possibly being the reason 
this strain displays an increased sensitivity to Hsp90 
inhibitors [27]). We found that this PP30-hsp82(E381K) 
also exhibits an extreme, FKBP12 (Fpr1)-dependent 
hypersensitivity to rapamycin (its growth being inhibited 
by just 1-2nM rapamycin; Fig. 5a). This sensitisation to 
rapamycin can be attributed to its high Hsf1 activity, since 
Hsf1 activation in the absence of heat stress is known to 
enhance sensitivity to rapamycin [28]. Moreover, unlike 
the normal Hsf1 activity of PP30-HSP82 cells expressing 
the wild type Hsp82, this elevated Hsf1 activity of PP30-
hsp82(E381K) - though still FKBP12-dependent - was not 
subject to inhibition by rapamycin (Fig. 5b). 
We found that rapamycin also did not inhibit the 
activation of Hsf1 in cells that lack the serine/threonine 
protein phosphatase Ppt1 (the ppt1∆ mutant, Fig. 5c). Ppt1, 
the yeast ortholog of mammalian protein phosphatase 5 
(PP5), is a dedicated regulator of the Hsp90 chaperone 
system, its N-terminal tetratricopeptide repeats (TPRs) 
interacting with the -EEVD motif found at the extreme 
C-terminus of cytosolic Hsp90s [48]. Finding that this 
ppt1∆ strain displayed a normal HSE-lacZ induction with 
stress, not inhibited by rapamycin, led us to investigate 
another strain in which the sole Hsp90 lacks its terminal 
–EEVD motif (PP30-hsp82(-EEVD); Table 1). In this 
PP30-hsp82(-EEVD) the HSE-lacZ induction with stress 
was only partially abolished under our conditions of 
rapamycin treatment (Fig. 5d). In contrast to hsp82-E381K 
cells, with their high basal HSE-lacZ expression (Fig. 
5b), the ppt1∆ mutant and the cells in which the Hsp90 
lacks the terminal –EEVD displayed essentially unaltered 
basal levels of HSE-lacZ expression (Fig. 5) as well as 
sensitivities to radicicol and rapamycin (not shown).
Together these results provide the first demonstration 
that the rapamycin inhibition of Hsf1 can be lost through 
Hsp90 mutation or with the loss of an Hsp90 system 
cochaperone. Rapamycin inhibition of Hsf1 is also lost 
with rapamycin resistance mutations (Fig. 2b), but these 
act by abolishing the rapamycin/FKBP12 complex binding 
to TORC1. In contrast the Hsp90 system defects analysed 
here do not generate rapamycin resistance (hsp82-E381K 
instead sensitising cells to this antibiotic (Fig. 5a)). It 
is quite probable therefore that these Hsp90 chaperone 
defects are preventing the rapamycin inhibition of HSE-
lacZ induction at the level of the Hsp90 suppression of 
Hsf1 activity. 
DISCUSSION
It is important to develop strategies for the 
inhibition of Hsf1, since this transcription factor is a 
driver of cancer progression and the Hsf1-directed heat 
shock response frequently causes a degree of resistance 
to Hsp90 inhibitor cancer drugs (see Introduction). This 
study has exploited well characterised mutants of yeast 
to investigate the rapamycin inhibition of the native Hsf1 
in this model organism; as well as how this is inhibition 
might be affected by the inhibition and mutation of the 
Hsp90 chaperone machine. Both in yeast and in human 
cells rapamycin and Hsp90 inhibitors have potent, yet 
opposing, effects on the activity of Hsf1. Rapamycin is 
an inhibitor of Hsf1 activity (Fig. 2b) [11], while Hsp90 
inhibitors are activators of Hsf1. The issue therefore 
arises of what happens to both growth inhibition and Hsf1 
activity when rapamycin is used in combination with an 
Hsp90 inhibitor. 
In this study we found little synergy between the 
inhibitory effects of rapamycin and the Hsp90 inhibitor 
radicicol on the growth of yeast, irrespective of whether 
the cells possessed a stress-inducible form of Hsf1 (Fig. 
1). This may be due to an overriding effect of rapamycin, 
which rapidly blocked any Hsf1 induction by the Hsp90 
inhibitor (Fig. 3a). Such findings contrast with those of 
a recent study in which mTOR inhibitors were found to 
potentiate the efficacy of the Hsp90 inhibitor ganetespib 
in several tumor cell lines [15]. Such differences - yeast 
versus tumor cells - are perhaps to be expected, especially 
considering the considerably less complex role of TORC1 
in yeast as compared to mammalian systems. 
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The novelty of this work is that it has provided the 
first demonstration that Hsp90 inhibitor resistance can be 
influenced by mutations causing resistance to rapamycin 
(Fig. 2a) and, conversely, that rapamycin resistance can be 
influenced by mutations in the Hsp90 chaperone machine 
(Fig. 5a). While rapamycin inhibits the activation of Hsf1, 
it is without any appreciable effect on immediate HSE-
lacZ expression in cells that substantially lack an inducible 
Hsf1 (e.g. tor1∆, fpr1∆; Fig. 3a). In yeast this inhibition of 
Hsf1 is not exerted through either Tap42 or Sch9, major 
downstream targets phosphorylated by TORC1 (Fig. 4). It 
may therefore reflect a more direct TORC1 activation of 
Hsf1. In human cells Hsf1 activation is known to require 
its TORC1-dependent phosphorylation of serine 326 [11]. 
The phosphorylation of this serine residue is attracting 
increased attention as a marker of the highly malignant 
state [49].
This study found that the TOR1.1, TOR2.1 and 
fpr1Δ rapamycin resistance mutations sensitise cells to 
Hsp90 inhibitor treatment (Fig. 2a, 3c) and abrogate the 
inducible heat shock response even in the absence of 
rapamycin (Fig. 2b,3a); that the rapamycin inhibition of 
Hsf1 activation does not involve the downstream TORC1 
regulation of Tap42 or Sch9; also that the rapamycin 
inhibition of Hsf1 can be overridden by Hsp90 mutation 
and with loss of an Hsp90 system cochaperone (Fig. 5). 
Notably we find that Hsf1 activation has a requirement for 
the rapamycin-binding immunophilin FKBP12, though not 
the peptidyl prolyl isomerise activity of this FKBP12 (Fig. 
3). It will be interesting to discover if the Hsf1 activation 
in human cells has a similar requirement for the conserved 
immunophilin FKBP12. 
In mammalian systems, the signalling downstream 
of TORC1 is considerably more complex than in yeast. 
However much of it still operates through S6K1 [16]. 
An extension of these yeast genetic studies therefore has 
the potential to reveal yet more details of how TORC1 
regulates Hsf1, how the inhibition of TORC1 acts to 
suppress the inducible heat shock response and how this 
inhibition, in turn, impacts on the Hsp90 suppression of 
Hsf1 activity. Many of the mechanisms uncovered this 
way are likely to be conserved, yeast to man. Furthermore 
the human Hsf1 can, by mutation, be rendered functional 
in yeast whereupon much of its regulation is found to be 
conserved in this model eukaryote [50, 51].
In aging cells and tissues the levels of TORC1 
activity are one of the factors driving senescence, with 
the result that decreases in this activity have the potential 
to slow aging [52]. In cancer drug therapy the aim is 
generally a downregulation of mTOR and Hsf1, whereas 
in healthy aging an increased Hsf1 activity should 
potentially be beneficial in that it will increase chaperone 
levels, thereby causing the improved proteostasis that 
could counteract sarcopenia and neurodegenerative disease 
[3, 10]. This study has found that the TORC1 regulation 
of the transient heat shock response of vegetative yeast 
occurs independently of Sch9 (ortholog of S6K1; Fig. 4). 
However a decreased activity of S6K, yet an increased 
activity of Hsf1 are increasingly being identified as two 
factors important for extending the chronological lifespan 
of model organisms [18, 19]. They are also - at least to 
a degree - interdependent, Hsf1 being essential for the 
extension to lifespan when S6K is downregulated in aging 
Caenorhabditis elegans [53]. Future studies will therefore 
need to address the issue of whether the TORC1 regulation 
of Hsf1, studied here in the inducible heat shock response 
of vegetative yeast cells, differs from how TORC1 might 
regulate Hsf1 in the normal processes of aging.
MATERIALS AND METHODS
Yeast strains used in this study are listed in Table 
1. These were routinely maintained on YPD (2% (w/v) 
bactopeptone, 1% yeast extract, 2% glucose) 1.5% agar 
plates. Transformations with a URA3 vector bearing a 
LacZ gene under heat shock element control (HSE-LacZ) 
and measurement of levels of β-galactosidase expression 
were as previously described [27]. Cultures containing this 
plasmid were grown on standard defined (SD) minus uracil 
dropout medium and subjected to stress and/or antibiotic 
treatment as described in the figure legends. For the study 
in Fig. 3c strain BY4741 fpr1∆ containing this HSE-LacZ 
vector was transformed with additional YCplac111-based 
LEU2 vectors bearing either the wild type or F43Y mutant 
forms of the FPR1 gene under native promoter control, 
then grown on SD minus uracil and leucine prior to 
measurements of their HSE-LacZ expression.
For drug sensitivity assays, overnight YPD cultures 
were either serially diluted, then pinned onto YPD agar 
containing the indicated antibiotic and the plates incubated 
as indicated in the figure legends; or they were inoculated 
into complete SD medium (1x105 cells/ml), this dilution 
being used to set up radicicol and rapamycin or radicicol 
and caffeine dose response matrixes (final volume 0.2 
ml/well) in 96-well microtiter plates. After 46h growth 
at 28°C the cells were re-suspended by agitation, their 
absorbance determined at 595 nm with a Multiskan Ascent 
platereader with correction for the background from 
the corresponding medium, and the data quantitatively 
displayed with color using the program Java Treeview 
1.1.3 (http://jtreeview.sourceforge.net/).
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